23andMe Q2 2025 Earnings Report

23andMe EPS Results

• Actual EPS: -$2.32
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

23andMe Revenue Results

• Actual Revenue: $44.07 million
• Expected Revenue: $50.30 million
• Beat/Miss: Missed by -$6.23 million
• YoY Revenue Growth: N/A

23andMe Announcement Details

• Quarter: Q2 2025
• Date: 11/12/2024
• Time: N/A

23andMe (NASDAQ:ME) Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.